Brokerages Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.63

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been given an average rating of “Buy” by the eight brokerages that are covering the stock, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $6.63.

TSHA has been the subject of several research analyst reports. Needham & Company LLC restated a “buy” rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research note on Monday, January 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Canaccord Genuity Group lifted their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Chardan Capital reiterated a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Finally, JMP Securities reissued a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of institutional investors have recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC lifted its stake in shares of Taysha Gene Therapies by 7.2% in the fourth quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company’s stock worth $34,600,000 after acquiring an additional 1,349,999 shares in the last quarter. Octagon Capital Advisors LP grew its stake in Taysha Gene Therapies by 128.6% during the 4th quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company’s stock valued at $18,078,000 after purchasing an additional 5,877,778 shares in the last quarter. Vanguard Group Inc. increased its holdings in Taysha Gene Therapies by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company’s stock worth $15,409,000 after purchasing an additional 641,305 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of Taysha Gene Therapies in the 4th quarter valued at approximately $8,650,000. Finally, Geode Capital Management LLC boosted its stake in shares of Taysha Gene Therapies by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company’s stock valued at $6,182,000 after buying an additional 9,591 shares during the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Performance

TSHA stock opened at $1.64 on Friday. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. The company has a market cap of $336.11 million, a price-to-earnings ratio of 2.60 and a beta of 0.92. The business has a fifty day simple moving average of $1.71 and a 200-day simple moving average of $2.00. Taysha Gene Therapies has a 52 week low of $1.19 and a 52 week high of $4.32.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.